374-01-6

Usage

Uses

1. Used as a Chemical Building Block:
1,1,1-Trifluoro-2-propanol is utilized as a chemical building block in various chemical reactions and processes due to its unique properties as a fluoroalcohol.
2. Used in Pharmaceutical Industry:
In the pharmaceutical industry, 1,1,1-trifluoro-2-propanol is used as a solvent for the synthesis of various drugs and active pharmaceutical ingredients. Its unique properties as a fluoroalcohol make it a valuable component in the development of new medications.
3. Used in Chemical Synthesis:
1,1,1-Trifluoro-2-propanol is employed as a solvent in chemical synthesis, particularly in the production of fluorinated compounds. Its ability to dissolve a wide range of substances and its compatibility with various reaction conditions make it a versatile choice for chemical synthesis processes.
4. Used in Research and Development:
Due to its unique properties, 1,1,1-trifluoro-2-propanol is also used in research and development for studying the effects of fluorination on various chemical reactions and exploring new applications in different fields, including materials science and pharmaceuticals.

InChI:InChI=1/C3H5F3O/c1-2(7)3(4,5)6/h2,7H,1H3/t2-/m0/s1

Upstream product

• 359-41-1 1,1,1-trifluoro-2,3-epoxypropane 
• 917-64-6 methyl magnesium iodide 
• 431-47-0 trifluoroacetic acid-methyl ester 
• 383-63-1 ethyl trifluoroacetate, 
• 75-90-1 2,2,2-Trifluoroacetaldehyde 
• 917-54-4 methyllithium 
• 421-50-1 1,1,1-trifluoro-2-propanone 
• 344324-54-5 trifluoroisopropyl fluorosulfite 
• 60-29-7 diethyl ether 
• 677-21-4 1,1,1-trifluoropropylene 
• 25015-63-8 4,4,5,5-tetramethyl-[1,3,2]-dioxaboralane 
• 274-07-7 benzo[1,3,2]dioxaborole 
• 637-50-3 1-phenylpropene 
• 130025-34-2 (S)-2-trifluoromethyl-oxirane 

Downstream Products

• 400-37-3 acetic acid-(β,β,β-trifluoro-isopropyl ester) 
• 58219-97-9 1,1,1-trifluoropropan-2-yl 4-methylbenzenesulfonate 
• 28049-07-2 3-Phenylpropionsaeure-1,1,1-trifluoro-2-propylester 
• 421-50-1 1,1,1-trifluoro-2-propanone 
• 32793-56-9 1,1,1-trifluoro-2-difluoromethoxypropane 
• 1156542-42-5 4-(2,2,2-trifluoro-1-methylethoxy)pyridine-2-carbonitrile 
• 1196485-88-7 4-[4-(4-methanesulfonyl-phenoxy)-pyrazolo[3,4-d]pyrimidin-1-yl]-piperidine-1-carboxylic acid 2,2,2-trifluoro-1-methyl-ethyl ester 
• 845616-83-3 rac-5-methanesulfonyl-2-(2,2,2-trifluoro-1-methylethoxy)benzoic acid 
• 87014-38-8 p-(1,1,1-Trifluoroisopropoxy)benzonitrile 
• 1255649-22-9 (rac)-1-nitro-4-(2,2,2-trifluoro-1-methyl-ethoxy)-benzene 
• 1446444-44-5 4-((5-chloro-6-((1,1,1-trifluoropropan-2-yl)oxy)pyridin-3-yl)oxy)-N-[(dimethylamino)sulfonyl]-2,5-difluorobenzamide 
• 374-01-6 (S)-1,1,1-trifluoro-2-propanol 
• 12582-61-5 μ-oxo-bis[α,β,γ,δ-tetraphenylporphinatoiron] 

Relevant academic research and scientific papers

ION CHANNEL MODULATORS

The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including neurological disorders (e.g., Dravet syndrome, epilepsy), pain, and neuromuscular disorders are also provided herein.

Method for oxidative cracking of compound containing unsaturated double bonds

The invention relates to a method for oxidative cracking of a compound containing unsaturated double bonds. The method comprises the following steps: (A) providing a compound (I) containing unsaturated double bonds, a trifluoromethyl-containing reagent and a catalyst, wherein the catalyst is shown as a formula (II): M(O)mL1yL2z (II), M, L1, L2, m, y, z, R1, R2 and R3 being defined in the specification; and (B) mixing the compound containing the unsaturated double bonds and the trifluoromethyl-containing reagent, and performing an oxidative cracking reaction on the compound containing the unsaturated double bonds in the presence of air or oxygen by using the catalyst to obtain a compound represented by formula (III),.

METHOD FOR OXIDATIVE CLEAVAGE OF COMPOUNDS WITH UNSATURATED DOUBLE BOND

A method for oxidative cleavage of a compound with an unsaturated double bond is provided. The method includes the steps of: (A) providing a compound (I) with an unsaturated double bond, a trifluoromethyl-containing reagent, and a catalyst; wherein, the catalyst is represented by Formula (II): M(O)mL1yL2z??(II);wherein, M, L1, L2, m, y, z, R1, R2 and R3 are defined in the specification; and(B) mixing the compound with an unsaturated double bond and the trifluoromethyl-containing reagent to perform an oxidative cleavage of the compound with the unsaturated double bond by using the catalyst in air or under oxygen atmosphere condition to obtain a compound represented by Formula (III):

METHOD FOR OXIDATIVE CLEAVAGE OF COMPOUNDS WITH UNSATURATED DOUBLE BOND

A method for oxidative cleavage of a compound with an unsaturated double bond is provided. The method comprises the following step: (A) providing a compound (I) with an unsaturated double bond, a reagent with trifluoromethyl, and a catalyst; wherein the catalyst is represented by the following formula (II): M(O)mL1yL2z (II); wherein, M, L1, L2, m, y, z, R1, R2 and R3 are defined in the specification; and (B) mixing the compound with an unsaturated double bond and the reagent with a trifluoromethyl to perform an oxidation of the compound with the unsaturated double bond by using the catalyst at air or an oxygen condition to get a compound presented as formula (III):

ION CHANNEL MODULATORS

Provided, in part, are compounds of Formula I pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of conditions associated with the activity of sodium channels. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including neurological disorders (e.g., Dravet syndrome, epilepsy), pain, and neuromuscular disorders are also provided herein.

COMPOUNDS AND THEIR METHODS OF USE

The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including Dravet syndrome or epilepsy are also provided herein.

COMPOUNDS AND THEIR METHODS OF USE

The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including neurological disorders (e.g., Dravet syndrome, epilepsy), pain, and neuromuscular disorders are also provided herein.

ION CHANNEL MODULATORS

The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including neurological disorders (e.g., Dravet syndrome, epilepsy), pain, and neuromuscular disorders are also provided herein.

N-(3-(2-(4-CHLOROPHENOXY)ACETAMIDO)BICYCLO[1.1.1]PENTAN-1-YL)-2-CYCLOBUTANE-1-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ATF4 INHIBITORS FOR TREATING CANCER AND OTHER DISEASES

The invention is directed to substituted bridged cycloalkane derivatives. Specifically, the invention is directed to compounds according to Formula (I) wherein X, a, b, C, D, L2,L3, Y1, Y2, R2, R4, R5, R6, z2, z4, z5, and z6 are as defined herein, and salts thereof. The invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to compounds for use in methods of inhibiting the ATF4 (activating transcription factor 4) pathway and treatment of disorders associated therewith, such as e.g. cancer, neurodegenerative diseases and many other diseases, using a compound of the invention or a pharmaceutical composition comprising a compound of the invention. Preferred compounds of the invention are N-(3-(2-(4-chlorophenoxy) acetamido)bicyclo[1.1.1]pentan-l-yl)-2-cyclobutane-l-carboxamide derivatives and related compounds.

Characterization of two carbonyl reductases from Ogataea polymorpha NBRC 0799

The enzyme responsible for the enantioselective production of (S)-1,1,1-trifluoro-2-propanol ((S)-TFP) from 1,1,1-trifluoroacetone (TFA) has been identified in Ogataea polymorpha NBRC 0799. We purified two carbonyl reductases, OpCRD-A and OpCRD-B from this strain, and revealed their characteristics. Both enzymes were specific to NADH, but the following characteristics were different: The molecular mass of subunit OpCRD-A was 40?kDa and that of OpCRD-B was 43?kDa. Amino acid sequences of both enzymes were only 21% identical. OpCRD-B contained 4?mol of zinc per mole of enzyme, but OpCRD-A did not. The optimal pH, temperature, pH stability, thermostability, and inhibitor specificity were also remarkably different. With regard to substrate specificity, both enzymes exhibited high reductase activity toward a wide variety of ketones, aldehydes and fluoroketones, and dehydrogenase activity toward 2-propanol and 2-butanol. The reductase activity was much higher than the dehydrogenase activity at acidic pH. OpCRD-A enantioselectively produced (S)-TFP from TFA, but OpCRD-B preferentially produced (R)-TFP. Thus, we concluded that OpCRD-A plays the main role in the production of (S)-TFP by a reaction of O. polymorpha NBRC 0799 cells and that OpCRD-A has great potential for efficient production of (S)-TFP, as it is an S-specific enzyme and does not catalyze the dehydrogenation of (S)-TFP.